Novartis voluntarily started a recall on August 4, 2026, of its valsartan product Diovan, according to an enforcement report released by the FDA on August 8, 2026. The recall was due to “Failed Dissolution Specifications.” Patheon Manufacturing Services LLC in Greenville, North Carolina, made the recalled lot, which has 160-milligram tablets in 90-count bottles. The lot number is AV5913C, and the tablets are good until June 2027. All of them. One certain group. Not all of the products.
Dissolution testing is the kind of quality check that doesn’t get a lot of attention when it works, but the pharmaceutical industry relies on it all the time. In a controlled lab setting, the test checks how a tablet breaks down and releases its active ingredient. If a tablet fails that test, it’s a big problem because people may be taking a pill that isn’t giving them the full dose their doctor prescribed. It’s not small for someone with high blood pressure to have a difference between their intended dose and their actual dose. Over days and weeks, blood pressure can slowly rise, and most of the time, there are no obvious signs until something goes wrong.
The FDA called this a Class II recall, which means “a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.” The way they say that is careful and measured. It means some things, but not all of them. Read it slowly before you decide what to do about your medicine.
A certain kind of alarm goes off very quickly when the word “recall” is spoken by patients who remember what happened with valsartan years ago. As of 2018, the FDA and health agencies around the world recalled large amounts of valsartan because it had been tainted by Zhejiang Huahai Pharmaceuticals in China. The tainted drugs contained possible carcinogens like NDMA.
That really was a serious situation. There is no doubt that this one is different. There was nothing strange in these tablets. Not a carcinogen. Do not contaminate. The problem is not chemical safety, but how consistently the products are made. If you mix them up, it could lead to unnecessary panic and do a lot more damage than the recall itself.
In the United States, about 10.9 million people were taking valsartan as of 2024, making it one of the most commonly prescribed heart drugs. So it makes sense that when a single lot is pulled, it gets people’s attention, even if the scope is small. Generic valsartan from other companies does not affect people who take it. They are also not on other strengths of Diovan or other lot numbers.
It only takes one small piece of information—the lot number on your bottle—to find out if you’re affected. Find AV5913C next to the date it expires in June 2027. As a practical matter, the problem is that many pharmacies give out medicine in their own labeled vials instead of handing over the original sealed container from the manufacturer. That means the lot number might not show up on what’s at home. This can be easily fixed by calling the dispensing pharmacy and asking them to look it up in the fill record.
Do not stop taking a blood pressure medicine because of a recall headline. This is the most important piece of advice that was buried in most of the news. Stopping valsartan or any other antihypertensive drug all of a sudden without medical advice can cause blood pressure to rise very quickly, which comes with its own serious risks. First, check the lot. Then, call the pharmacy and get a replacement from a batch that isn’t affected. Medical professionals tell patients that they shouldn’t stop taking their blood pressure medicine without first talking to their doctor.
There is a bigger pattern that needs to be seen. Problems with dissolving this type of drug are not unique; in the past few months, similar problems have been found with other heart medicines, leading to the same cycle of news stories, patient worry, and cautious FDA classification. It’s still not clear whether that’s because of stricter rules, more work for domestic contract manufacturers in the supply chain, or just better testing after the product has been sold. Not as unclear is the fact that this one was caught by the system before it did any real damage.
